Distinct Pathogenesis of Pancreatic Cancer Microvesicle-Associated Venous Thrombosis Identifies New Antithrombotic Targets in Vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 38, Issue 4, 2018, Pages 772-786

  Stark, Konstantin ^a,b   Schubert, Irene ^a   Joshi, Urjita ^c   Kilani, Badr ^a   Hoseinpour, Parandis ^a   Thakur, Manovriti ^c   Grünauer, Petra ^c   Pfeiler, Susanne ^c   Schmidergall, Tobias ^a   Stockhausen, Sven ^a   Bäumer, Markus ^c   Chandraratne, Sue ^a   Von Brühl, Marie Luise ^a   Lorenz, Michael ^a   Coletti, Raffaele ^a   Reese, Sven ^d   Laitinen, Iina ^e   Wörmann, Sonja Maria ^f   Algül, Hana ^f   Bruns, Christiane J ^g   Ware, Jerry ^h   Mackman, Nigel ⁱ   Engelmann, Bernd ^c   Massberg, Steffen ^a,b   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c Campus Benjamin Franklin   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Nuklearmedizinische Klinik und Poliklinik   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

adenocarcinoma; factor X; leukocytes; phosphatidylethanolamine; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; DABIGATRAN ETEXILATE; ENOXAPARIN; LANCOVUTIDE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID PHOSPHATIDYLETHANOLAMINE; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; BACTERIOCIN; BLOOD CLOTTING FACTOR 10A; FIBRINOLYTIC AGENT; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CAVA VEIN; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LEUKOCYTE; MEMBRANE MICROPARTICLE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC ADENOCARCINOMA CELL LINE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE; THROMBOSIS; VEIN THROMBOSIS; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; DRUG DESIGN; DRUG EFFECT; INFERIOR CAVA VEIN; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; BACTERIOCINS; BLOOD COAGULATION; CELL LINE, TUMOR; CELL-DERIVED MICROPARTICLES; DISEASE MODELS, ANIMAL; DRUG DESIGN; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; SIGNAL TRANSDUCTION; THROMBOPLASTIN; VENA CAVA, INFERIOR; VENOUS THROMBOSIS;

EID: 85044380678     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.310262     Document Type: Article

References (73)

1. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer. 2010;103:947-953. doi: 10.1038/sj.bjc.6605883.
2. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632-634. doi: 10.1111/j.1538-7836.2007.02374.x.
3. Thaler J, Ay C, Mackman N, Bertina RM, Kaider A, Marosi C, Key NS, Barcel DA, Scheithauer W, Kornek G, Zielinski C, Pabinger I. Microparticleassociated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012;10:1363-1370. doi: 10.1111/j.1538-7836.2012.04754.x.
4. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712-1723. doi: 10.1182/blood-2013-04-460121.
5. Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS, Mackman N, Iyer RV. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013;132:180-184. doi: 10.1016/j.thromres.2013.06.026.
6. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost. 2017;117:219-230. doi: 10.1160/TH16-08-0615.
7. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108:1284-1297. doi: 10.1161/CIRCRESAHA.110.233056.
8. Reinhardt C, von Brühl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, Dlugai S, Hess S, Konrad I, Orschiedt L, Mackman N, Ruddock L, Massberg S, Engelmann B. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest. 2008;118:1110-1122. doi: 10.1172/JCI32376.
9. Wang JG, Williams JC, Davis BK, Jacobson K, Doerschuk CM, Ting JP, Mackman N. Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. Blood. 2011;118:2366-2374. doi: 10.1182/ blood-2011-01-330878.
10. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122:1873-1880. doi: 10.1182/blood-2013-04-460139.
11. Date K, Hall J, Greenman J, Maraveyas A, Madden LA. Tumour and microparticle tissue factor expression and cancer thrombosis. Thromb Res. 2013;131:109-115. doi: 10.1016/j.thromres.2012.11.013.
12. Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R, Dee R, Cooley BC, Key NS, Wolberg AS, Bergmeier W, Mackman N. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost. 2016;14:153-166. doi: 10.1111/ jth.13181.
13. Hisada Y, Ay C, Auriemma AC, Cooley BC, Mackman N. Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size. J Thromb Haemost. 2017;15:2208-2217. doi: 10.1111/jth.13809.
14. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130:1499-1506. doi: 10.1182/ blood-2017-03-743211.
15. Manly DA, Wang J, Glover SL, Kasthuri R, Liebman HA, Key NS, Mackman N. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res. 2010;125:511-512. doi: 10.1016/j.thromres.2009.09.019.
16. Thomas GM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, Wagner DD. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost. 2015;13:1310-1319. doi: 10.1111/jth.13002.
17. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009;206:1913-1927. doi: 10.1084/jem.20082297.
18. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 1993;74:541-554.
19. Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood. 2002;100:2102-2107. doi: 10.1182/blood-2002-03-0997.
20. Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest. 1998;101:560-569. doi: 10.1172/JCI814.
21. Pawlinski R, Wang JG, Owens AP III, Williams J, Antoniak S, Tencati M, Luther T, Rowley JW, Low EN, Weyrich AS, Mackman N. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood. 2010;116:806-814. doi: 10.1182/ blood-2009-12-259267.
22. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265-277.
23. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209:819-835. doi: 10.1084/jem.20112322.
24. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia. 1999;1:50-62.
25. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469-483. doi: 10.1016/j.ccr.2005.04.023.
26. Vezeridis MP, Tzanakakis GN, Meitner PA, Doremus CM, Tibbetts LM, Calabresi P. In vivo selection of a highly metastatic cell line from a human pancreatic carcinoma in the nude mouse. Cancer. 1992;69:2060-2063.
27. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14:195-208. doi: 10.1038/nri3622.
28. Larson MC, Woodliff JE, Hillery CA, Kearl TJ, Zhao M. Phosphatidylethanolamine is externalized at the surface of microparticles. Biochim Biophys Acta. 2012;1821:1501-1507. doi: 10.1016/j. bbalip.2012.08.017.
29. Falls LA, Furie B, Furie BC. Role of phosphatidylethanolamine in assembly and function of the factor IXa-factor VIIIa complex on membrane surfaces. Biochemistry. 2000;39:13216-13222.
30. Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry. 1995;34:13988-13993.
31. Baumgärtner P, Geiger M, Zieseniss S, Malleier J, Huntington JA, Hochrainer K, Bielek E, Stoeckelhuber M, Lauber K, Scherfeld D, Schwille P, Wäldele K, Beyer K, Engelmann B. Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor. J Cell Biol. 2007;179:793-804. doi: 10.1083/jcb.200707165.
32. Yates KR, Welsh J, Echrish HH, Greenman J, Maraveyas A, Madden LA. Pancreatic cancer cell and microparticle procoagulant surface characterization: involvement of membrane-expressed tissue factor, phosphatidylserine and phosphatidylethanolamine. Blood Coagul Fibrinolysis. 2011;22:680-687. doi: 10.1097/MBC.0b013e32834ad7bc.
33. van den Besselaar AM. Phosphatidylethanolamine and phosphatidylserine synergistically promote heparin's anticoagulant effect. Blood Coagul Fibrinolysis. 1995;6:239-244.
34. van den Besselaar AM, Neuteboom J, Bertina RM. Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin. Blood Coagul Fibrinolysis. 1993;4:895-903.
35. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352. doi: 10.1056/ NEJMoa0906598.
36. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Köllnberger M, Wakefield TW, Lämmle B, Massberg S, Wagner DD. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117:1400-1407. doi: 10.1182/ blood-2010-05-287623.
37. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959-1967. doi: 10.1056/ NEJMoa1114238.
38. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10:136-144. doi: 10.1111/j.1538-7836.2011.04544.x.
39. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107:15880-15885.
40. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012;32:1777-1783. doi: 10.1161/ATVBAHA.111.242859.
41. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 1996;56:4244-4249.
42. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5:520-527. doi: 10.1111/j.1538-7836.2007.02369.x.
43. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853-862. doi: 10.1172/JCI18882.
44. Mege D, Mezouar S, Dignat-George F, Panicot-Dubois L, Dubois C. Microparticles and cancer thrombosis in animal models. Thromb Res. 2016;140(suppl 1):S21-S26. doi: 10.1016/S0049-3848(16)30094-9.
45. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34-45. doi: 10.1038/nri3345.
46. Stark K, Philippi V, Stockhausen S, et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood. 2016;128:2435-2449. doi: 10.1182/blood-2016-04-710632.
47. Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jelicic J, Hayman S, Mihaljevic B. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol. 2016;91:1014-1019. doi: 10.1002/ajh.24466.
48. Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M; RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013;131:24-30. doi: 10.1016/j. thromres.2012.10.007.
49. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol). 1999;11:105-110.
50. Yang SS, Yu CS, Yoon YS, Yoon SN, Lim SB, Kim JC. Symptomatic venous thromboembolism in Asian colorectal cancer surgery patients. World J Surg. 2011;35:881-887. doi: 10.1007/s00268-011-0957-2.
51. Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, Wagner DD. The role of platelet adhesion receptor gpibalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A. 2006;103:16900-16905.
52. Konstantinides S, Ware J, Marchese P, Almus-Jacobs F, Loskutoff DJ, Ruggeri ZM. Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. J Thromb Haemost. 2006;4:2014-2021. doi: 10.1111/j.1538-7836.2006.02086.x.
53. Shai A, Rennert HS, Lavie O, Ballan-Haj M, Bitterman A, Steiner M, Keren S, Rennert G. Statins, aspirin and risk of venous thromboembolic events in breast cancer patients. J Thromb Thrombolysis. 2014;38:32-38. doi: 10.1007/s11239-013-1015-8.
54. Shai A, Rennert HS, Rennert G, Sagi S, Leviov M, Lavie O. Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecol Oncol. 2014;133:304-308. doi: 10.1016/j.ygyno.2014.03.006.
55. Riedl J, Hell L, Kaider A, Koder S, Marosi C, Zielinski C, Panzer S, Pabinger I, Ay C. Association of platelet activation markers with cancerassociated venous thromboembolism. Platelets. 2016;27:80-85. doi: 10.3109/09537104.2015.1041901.
56. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119:933-939; quiz 1093. doi: 10.1182/ blood-2011-03-344333.
57. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29:986-993. doi: 10.1200/JCO.2010.31.6844.
58. Mezouar S, Frère C, Darbousset R, Mege D, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C. Role of platelets in cancer and cancerassociated thrombosis: experimental and clinical evidences. Thromb Res. 2016;139:65-76. doi: 10.1016/j.thromres.2016.01.006.
59. Riedl J, Preusser M, Nazari PM, Posch F, Panzer S, Marosi C, Birner P, Thaler J, Brostjan C, Lotsch D, Berger W, Hainfellner JA, Pabinger I, Ay C. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017;129:1831-1839. doi: 10.1182/blood-2016-06-720714.
60. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582-588. doi: 10.1182/ blood-2014-08-531582.
61. Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, Forsyth J, Maruszak B, Gartner TK, Felding-Habermann B, Ware J. Platelet glycoprotein ib alpha supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104:9024-9028.
62. Mezouar S, Darbousset R, Dignat-George F, Panicot-Dubois L, Dubois C. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer. 2015;136:462-475. doi: 10.1002/ ijc.28997.
63. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178-185. doi: 10.1182/ blood-2004-06-2272.
64. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16:887-896. doi: 10.1038/nm.2184.
65. Ripplinger CM, Kessinger CW, Li C, Kim JW, McCarthy JR, Weissleder R, Henke PK, Lin CP, Jaffer FA. Inflammation modulates murine venous thrombosis resolution in vivo: assessment by multimodal fluorescence molecular imaging. Arterioscler Thromb Vasc Biol. 2012;32:2616-2624. doi: 10.1161/ATVBAHA.112.251983.
66. Varma MR, Varga AJ, Knipp BS, Sukheepod P, Upchurch GR, Kunkel SL, Wakefield TW, Henke PK. Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg. 2003;38:1090-1098. doi: 10.1016/S0741.
67. Degen JL, Palumbo JS. Hemostatic factors, innate immunity and malignancy. Thromb Res. 2012;129(suppl 1):S1-S5. doi: 10.1016/ S0049-3848(12)70143-3.
68. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007;110:133-141. doi: 10.1182/blood-2007-01-065995.
69. Aharon A, Tamari T, Brenner B. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost. 2008;100:878-885.
70. Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem. 1999;274:23111-23118.
71. Yu J, May L, Milsom C, Anderson GM, Weitz JI, Luyendyk JP, Broze G, Mackman N, Rak J. Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol. 2008;28:1975-1981. doi: 10.1161/ATVBAHA.108.175083.
72. Magnus N, D'Asti E, Garnier D, Meehan B, Rak J. Brain neoplasms and coagulation. Semin Thromb Hemost. 2013;39:881-895. doi: 10.1055/s-0033-1357483.
73. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153. doi: 10.1056/NEJMoa025313.